New agents for the treatment of ovarian cancer: the next generation
- 1 November 2005
- journal article
- review article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 15 (s3) , 252-257
- https://doi.org/10.1111/j.1525-1438.2005.00443.x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancerGynecologic Oncology, 2005
- Phase II Study of CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaJournal of Clinical Oncology, 2004
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- Adjuvant Treatment for Early Ovarian Cancer: A Randomized Phase III Trial of Intraperitoneal 32P or Intravenous Cyclophosphamide and Cisplatin—A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 FunctionJournal of Biological Chemistry, 2002
- Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathwaysOncogene, 2002
- Mechanoelectrical and Voltage-Gated Ion Channels in Mammalian Vestibular Hair CellsAudiology and Neurotology, 2002
- Intraperitoneal Chemotherapy for Ovarian Carcinoma: Results of Long-Term Follow-UpJournal of Clinical Oncology, 2002
- Molecular Cloning of the CA125 Ovarian Cancer AntigenJournal of Biological Chemistry, 2001
- Augmentation of a humanized Anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225Oncogene, 1999